

**Novel diphenylazetidinones, process for their preparation,  
medicaments comprising these compounds and their use**


This application claims the benefit of priority under 35 U.S.C. § 119(a) to German  
5 patent application no. 10064398.1, filed on December 21, 2000, and German patent  
application no. 10152981.3, filed on October 26, 2001. The contents of both priority  
documents are incorporated by reference herein.

10 The invention relates to substituted diphenylazetidinones, to their physiologically  
acceptable salts and to derivatives having physiological function.

15 Diphenylazetidinones (such as, for example, ezetimibe) and their use for treating  
hyperlipidemia and arteriosclerosis and hypercholesterolemia have already been  
described [cf. Drugs of the Future 2000, 25(7):679-685 and US 5,756,470].

20 It was an object of the invention to provide further compounds having a  
therapeutically utilizable hypolipidemic action. In particular, it was an object to find  
novel compounds which, compared to the compounds described in the prior art, are  
absorbed to a very low extent. Very low absorption is to be understood as meaning  
an intestinal absorption of less than 10%, preferably less than or equal to 5%.  
In particular, absorption of the novel compounds should be less than that of  
ezetimibe. Pharmaceutically active compounds which are absorbed to a very low  
extent generally have considerably fewer side-effects.

Accordingly, an embodiment of the invention relates to compounds of the formula I,



I

5

in which

R1, R2, R3, R4, R5, R6 independently of one another are ( $C_0-C_{30}$ )-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -CH=CH-, -C≡C-, -N(( $C_1-C_6$ )-alkyl)-, -N(( $C_1-C_6$ )-alkylpenyl) or -NH-; or

10 H, F, Cl, Br, I,  $CF_3$ ,  $NO_2$ , CN, COOH,  $COO(C_1-C_6)$ -alkyl,  $CONH_2$ ,  $CONH(C_1-C_6)$ -alkyl,  $CON[(C_1-C_6)$ -alkyl]<sub>2</sub>, ( $C_1-C_6$ )-alkyl, ( $C_2-C_6$ )-alkenyl, ( $C_2-C_6$ )-alkynyl or O-( $C_1-C_6$ )-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; or

15  $SO_2-NH_2$ ,  $SO_2NH(C_1-C_6)$ -alkyl,  $SO_2N[(C_1-C_6)$ -alkyl]<sub>2</sub>, S-( $C_1-C_6$ )-alkyl, S-( $CH_2$ )<sub>n</sub>-phenyl, SO-( $C_1-C_6$ )-alkyl, SO-( $CH_2$ )<sub>n</sub>-phenyl,  $SO_2-(C_1-C_6)$ -alkyl or  $SO_2-(CH_2)_n$ -phenyl, where n = 0 – 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH,  $CF_3$ ,  $NO_2$ , CN,  $OCF_3$ ,

20 O-( $C_1-C_6$ )-alkyl, ( $C_1-C_6$ )-alkyl or  $NH_2$ ; or  $NH_2$ ,  $NH-(C_1-C_6)$ -alkyl,  $N((C_1-C_6)$ -alkyl)<sub>2</sub>,  $NH(C_1-C_7)$ -acyl, phenyl or O-( $CH_2$ )<sub>n</sub>-phenyl, where n = 0 – 6, where the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, OH,  $CF_3$ ,  $NO_2$ , CN,  $OCF_3$ , O-( $C_1-C_6$ )-

alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or CONH<sub>2</sub>;

(LAG) is a sugar residue, disugar residue, trisugar residue, tetrasugar residue;

5 a sugar acid, an amino sugar;

an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids; or

a trialkylammoniumalkyl radical; or -O-(SO<sub>2</sub>)-OH;

10 wherein at least one of the radicals R1 or R6 has the meaning

(C<sub>0</sub>-C<sub>30</sub>)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -CH=CH-, -C≡C-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkylpenyl) or -NH-, and where the radicals R1 and R2 may not have the meaning -O-sugar residue or -O-sugar acid,

15 and its pharmaceutically acceptable salts.

Another embodiment of the invention relates to compounds of the formula I, in which at least one of the radicals R1 to R6 has the meaning (C<sub>0</sub>-C<sub>30</sub>)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)-, or -NH-.

Another embodiment of the invention relates to compounds of the formula I, in which one of the radicals R1 or R3 has the meaning (C<sub>0</sub>-C<sub>30</sub>)-alkylene-(LAG), where one or more carbon atoms of the alkylene radicals may be replaced by -O-, -(C=O)-, -

25 N(CH<sub>3</sub>)-, or -NH-.


Another embodiment of the invention relates to compounds of the formula I, in which one of the radicals R1 or R3 has the meaning -(CH<sub>2</sub>)<sub>0-1</sub>-NH-(C=O)<sub>0-1</sub>-(C<sub>0</sub>-C<sub>25</sub>)-alkylene-(C=O)<sub>0-1</sub>-N(R7)<sub>0-1</sub>-(LAG); where one or more carbon atoms of the alkylene

30 radical may be replaced by oxygen atoms and where R7 is H or CH<sub>3</sub>.

Another embodiment of the invention relates to compounds of the formula I in which the group LAG is a monosugar residue.

A trialkylammonium alkyl radical is to be understood as meaning the following group

5



in which n = 0 to 10 and Alk<sub>1</sub>, Alk<sub>2</sub>, Alk<sub>3</sub> independently of one another each denote a straight-chain or branched alkyl radical having 1 to 20 carbon atoms.

10

Owing to their increased solubility in water, compared to the parent compounds, pharmaceutically acceptable salts are particularly suitable for medical applications. These salts should have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and of organic acids, such as acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isothionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid, tartaric acid and trifluoroacetic acid, for example. For medical purposes, very particular preference is given to using the chloride salt. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).

20

25

The scope of the invention also includes salts having a pharmaceutically unacceptable anion, which salts may be useful intermediates for preparing or purifying pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.

5

Here, the term "derivative having physiological function" refers to any physiologically acceptable derivative of a compound according to the invention, for example an ester, capable of forming, upon administration to a mammal, for example man, to form such a compound or an active metabolite (directly or indirectly).

10

A further aspect of this invention are prodrugs of the compounds according to the invention. Such prodrugs can be metabolized in vivo to give a compound according to the invention. These prodrugs may or may not be active in their own right.

卷之三

15

The compounds according to the invention can also be present in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. The scope of the invention includes all polymorphous forms of the compounds according to the invention, which form a further aspect of the invention. The compounds of the invention may also exist in the form of solvates.

20

The compounds of the formula I and their pharmaceutically acceptable salts, esters and prodrugs and derivatives having physiological function are ideal medicaments for treating an impaired lipid metabolism, in particular hyperlipidemia. The compounds of the formula I are also suitable for modulating the serum cholesterol concentration and for treating arteriosclerotic manifestations. The compounds of the invention are also suitable for the treatment of insulin resistance.

25

As used here, "treatment" or "therapy" of a condition and "treating" a condition can mean successfully eliminating the condition, reducing the effects associated with it, and/or reducing its severity. It also includes administering the relevant compounds to

a patient to avoid recurrence of a condition. It also includes avoiding the onset of a condition by administering the relevant compounds to patients falling into a risk group or category for developing the particular condition. Those skilled in the art can routinely identify patients likely to present with a given condition, thereby qualifying

5 as candidates for treatment.

The compound(s) of the formula (I) can also be administered in combination with other active compounds.

10 The amount of a compound of the formula (I) required to achieve the desired biological effect depends on a number of factors, for example on the specific compound chosen, on the intended use, on the mode of administration and on the clinical condition of the patient. In general, the daily dose is in the range from 0.1 mg to 100 mg (typically from 0.1 mg to 50 mg) per day per kilogram of bodyweight, for example 0.1-10 mg/kg/day. Tablets or capsules may contain, for example, from 0.01 to 100 mg, typically from 0.02 to 50 mg. In the case of pharmaceutically acceptable salts, the abovementioned weight data relate to the weight of the diphenyl-15 azetidinone-ion derived from the salt. For the therapy of the abovementioned conditions, the compounds of the formula (I) can be used themselves as the compound, but preferably they are present in the form of a pharmaceutical composition with an acceptable carrier. The carrier must of course be acceptable in the sense that it is compatible with the other constituents of the composition and is not harmful to the health of the patient. The carrier can be a solid or a liquid or both and is preferably formulated with the compound as an individual dose, for example 20 as a tablet, which can contain from 0.05% to 95% by weight of the active compound. Further pharmaceutically active substances can also be present, including further compounds of the formula (I). The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which 25 essentially consist in mixing the constituents with pharmacologically acceptable carriers and/or auxiliaries.

Pharmaceutical compositions according to the invention are those which are suitable for oral or peroral (e.g. sublingual) administration, although the most suitable manner of administration is dependent in each individual case on the nature and severity of

5 the condition to be treated and on the type of the compound of the formula (I) used in each case. Coated formulations and coated delayed-release formulations are also included in the scope of the invention. Acid-resistant and enteric formulations are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of

10 methacrylic acid and methylmethacrylate.

Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, lozenges or tablets, which in each case contain a specific amount of the compound of the formula (I); as a

15 powder or granules; as a solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared according to any suitable pharmaceutical method which includes a step in which the active compound and the carrier (which can consist of one or more additional constituents) are brought into contact. In general,

20 the compositions are prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid carrier, after which the product, if necessary, is shaped. For example, a tablet can thus be prepared by pressing or shaping a powder or granules of the compound, if appropriate with one or more additional constituents. Pressed tablets can be produced by tableting the compound

25 in free-flowing form, such as, for example, a powder or granules, if appropriate mixed with a binder, lubricant, inert diluent and/or a (number of) surface-active/dispersing agent(s) in a suitable machine. Shaped tablets can be produced by shaping the pulverulent compound moistened with an inert liquid diluent in a suitable machine.

Pharmaceutical compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound of the formula (I) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which include the compound in an inert base such as gelatin and glycerol or sucrose and

5 gum arabic.

Suitable other active compounds for the combination preparations include: all antidiabetics, mentioned in Rote Liste 2001, Chapter 12, the disclosure of which is incorporated by reference herein. They can be combined with the compounds of

10 the formula I according to the invention in particular to achieve a synergistically enhanced action. The active compound combination can be administered either by separate administration of the active compounds to the patient or in the form of combination preparations comprising a plurality of active compounds in a pharmaceutical preparation.

15 Antidiabetics include insulin and insulin derivatives, such as, for example, Lantus® or HMR 1964, GLP-1 derivatives, such as, for example, those disclosed by Novo Nordisk A/S in WO 98/08871, the disclosure of which is incorporated by reference herein, and oral hypoglycemic active compounds.

20 The oral hypoglycemic active compounds preferably include sulfonyl ureas, biguadines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potassium channel openers, such as, for example, those disclosed by Novo Nordisk A/S in WO 97/26265 and

25 WO 99/03861, the disclosures of which are incorporated by reference herein, insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds which modulate lipid metabolism, such as antihyperlipidemic active compounds and antilipidemic active compounds, compounds which reduce food intake, PPAR and PXR agonists and active compounds which act on the ATP-dependent potassium channel of the

beta cells.

In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as

5 simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.

In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor, such as, for example, ezetimibe, tiqueside, pamaqueside.

10

In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR gamma agonist, such as, for example, rosiglitazone, pioglitazone, JTT-501, GI 262570.

15

In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR alpha agonist, such as, for example, GW 9578, GW 7647.

20

In one embodiment of the invention, the compounds of the formula I are administered in combination with a mixed PPAR alpha/gamma agonist, such as, for example, GW 1536, AVE 8042, AVE 8134, AVE 0847.

25

In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate, such as, for example, fenofibrate, clofibrate, bezafibrate.

In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor, such as, for example, Bay 13-9952, BMS-201038, R-103757.

30

In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid absorption inhibitor, such as, for example, HMR 1453.

5 In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, such as, for example, Bay 194789.

10 In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorber, such as, for example, cholestyramine, colesolvam.

15 In one embodiment of the invention, the compounds of the formula I are administered in combination with an LDL receptor inducer, such as, for example, HMR1171, HMR1586.

20 In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor, such as, for example, avasimibe.

In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant, such as, for example, OPC-14117.

25 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor, such as, for example, NO-1886.

30 In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP citrate lyase inhibitor, such as, for example, SB-204990.

In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor, such as, for example, BMS-188494.

5

In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist, such as, for example, CI-1027 or nicotinic acid.

10 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor, such as, for example, Orlistat.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

In one embodiment of the invention, the compounds of the formula I are administered in combination with insulin.

15 In one embodiment, the compounds of the formula I are administered in combination with a sulfonyl urea, such as, for example, tolbutamide, glibenclamide, glipizide or gliclazide.

20 In one embodiment, the compounds of the formula I are administered in combination with a biguanide, such as, for example, metformin.

In another embodiment, the compounds of the formula I are administered in combination with a meglitinide, such as, for example, repaglinide.

25

In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione, such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone, or the compounds disclosed by Dr. Reddy's Research Foundation in WO 97/41097, the disclosure of which is incorporated by reference herein, in

particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.

In one embodiment, the compounds of the formula I are administered in combination  
5 with an  $\alpha$ -glucosidase inhibitor, such as, for example, miglitol or acarbose.

In one embodiment, the compounds of the formula I are administered in combination  
with an active compound which acts on the ATP-dependent potassium channel of  
beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, gliazide or  
10 repaglinide.

In one embodiment, the compounds of the formula I are administered in combination  
with more than one of the abovementioned compounds, for example in combination  
with a sulfonyl urea and metformin, a sulfonyl urea and acarbose, repaglinide and  
15 metformin, insulin and a sulfonyl urea, insulin and metformin, insulin and troglitazon,  
insulin and lovastatin, etc.

In a further embodiment, the compounds of the formula I are administered in  
combination with CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3  
20 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists,  $\beta$ 3-  
agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin  
reuptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists,  
bombesin agonists, galanin antagonists, growth hormone, growth hormone-releasing  
compounds, TRH agonists, decoupling protein 2- or 3 modulators, leptin agonists,  
25 DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR modulators,  
RXR modulators or TR- $\beta$  agonists.

In one embodiment of the invention, the further active compound is leptin.

In one embodiment, the further active compound is dexamphetamine or amphetamine.

In one embodiment, the further active compound is fenfluramine or dexfenfluramine.

5

In another embodiment, the further active compound is sibutramine.

In one embodiment, the further active compound is Orlistat.

10 In one embodiment, the further active compound is mazindol or phentermine.


11  
12  
13  
14  
15  
16  
17  
18  
19  
20

In one embodiment, the compounds of the formula I are administered in combination with fiber, preferably insoluble fiber, such as, for example, Caromax®. The combination with Caromax® can be given in one preparation or by separate administration of compounds of the formula I and Caromax®. Here, Caromax® can also be administered in the form of food, such as, for example, in bakery goods or muesli bars. Compared to the individual active compounds, the combination of compounds of the formula I with Caromax® is, in addition to an enhanced action, in particular with respect to the lowering of LDL cholesterol, also characterized by its improved tolerability.

25 It goes without saying that each suitable combination of the compounds according to the invention with one or more of the compounds mentioned above and optionally one or more further pharmacologically active substances is included in the scope of the present invention.

30 The invention furthermore provides both stereoisomer mixtures of the formula I and the pure stereoisomers of the formula I, and diastereomer mixtures of the formula I and the pure diastereomers. The mixtures are separated by chromatographic means.

Preference is given to both racemic and enantiomerically pure compounds of the formula I of the following structure:



5 Sugar residues are to be understood as meaning compounds which are derived  
 - from aldoses and ketoses which have 3 to 7 carbon atoms and may belong to the D  
 or the L series; also included are amino sugars, sugar alcohols or sugar acids.  
 10 Glucose, mannose, fructose, galactose, ribose, erythrose, glycerolaldehyde,  
 sedoheptulose, glucosamine, galactosamine, glucuronic acid, galacturonic acid,  
 gluconic acid, galactonic acid, mannonic acid, glucamine, 3-amino-1,2-propanediol,  
 glucaric acid and galactaric acid may be mentioned by way of example.

15 Disugars are saccharides composed of two sugar units. Di-, tri- or tetrasaccharides  
 are formed by acetal-like binding of two or more sugars. Here, the bonds may be in  
 the  $\alpha$ - or  $\beta$ -form. Lactose, maltose and cellobiose may be mentioned by way of  
 example.

20 If the sugar is substituted, the substitution is preferably at the hydrogen atom of an  
 OH group of the sugar.

Suitable protective groups for the hydroxyl groups of the sugars are substantially:  
 benzyl, acetyl, benzoyl, pivaloyl, trityl, tert-butyldimethylsilyl, benzylidene,  
 cyclohexylidene or isopropylidene protective groups.

The term "amino acids" or "amino acid residues" refers, for example, to the stereoisomeric forms, i.e. the D or L forms, of the following compounds:

5	alanine	glycine	proline
	cysteine	histidine	glutamine
	aspartic acid	isoleucine	arginine
	glutamic acid	lysine	serine
	phenylalanine	leucine	threonine
10	tryptophan	methionine	valine
	tyrosine	asparagine	
15	2-amino adipic acid	2-amino isobutyric acid	
	3-amino adipic acid	3-amino isobutyric acid	
	beta-alanine	2-aminopimelic acid	
	2-aminobutyric acid	2,4-diaminobutyric acid	
	4-aminobutyric acid	desmosine	
	piperidine carboxylic acid	2,2-diaminopimelic acid	
20	6-aminocaproic acid	2,3-diaminopropionic acid	
	2-aminoheptanoic acid	N-ethylglycine	
	2-(2-thienyl)glycine	3-(2-thienyl)alanine	
	penicillamine	sarcosine	
	N-ethylasparagine	N-methylisoleucine	
25	hydroxylysine	6-N-methyllysine	
	allo-hydroxylysine	N-methylvaline	
	3-hydroxyproline	norvaline	
	4-hydroxyproline	norleucine	
	isodesmosine	ornithine	
30	allo-isoleucine		

N-methylglycine

For abbreviating the amino acids, the conventional notation was used (cf. Schröder, Lübke, The Peptides, Volume I, New York 1965, pages XXII-XXIII; Houben-Weyl,

5 Methoden der Organischen Chemie [Methods of organic chemistry], Volume XV/1 and 2, Stuttgart 1974). The amino acid pGlu denotes pyroglutamyl, Nal denotes 3-(2-naphthyl)alanine, azagly-NH<sub>2</sub> denotes a compound of the formula NH<sub>2</sub>-NH-CONH<sub>2</sub> and D-Asp denotes the D form of aspartic acid. According to their chemical nature, peptides are acid amides, and on hydrolysis they decompose into amino

10 acids.

An oligopeptide is to be understood as meaning a peptide constructed of 2 to 9 of the amino acids mentioned above.


15 Suitable protective groups (see, for example, T.W. Greene, "Protective Groups in Organic Synthesis") for amino acids are primarily: Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMV), Asp(OBzl), Asp(Obut), Cys(4-MeBzl), Cys(Acm), Cys(SBut), Glu(Obzl), Glu(Obut), His(Tos), His(Fmoc), His(Dnp), His(Trt), Lys(Cl-Z), Lys(Boc), Met(O), Ser(Bzl), Ser(But), Thr(Bzl), Thr(But), Trp(Mts),

20 Trp(CHO), Tyr(Br-Z), Tyr(Bzl) or Tyr(But).

Amino protective groups that are preferably used are the benzyloxycarbonyl (Z) radical, which can be removed by catalytic hydrogenation, the 2-(3,5-dimethoxyphenyl)propyl(2)oxycarbonyl(Ddz) or trityl (Trt) radical, which can be

25 removed by weak acids, and the 9-fluorenylmethyloxycarbonyl (Fmoc) radical, which can be removed using secondary amines.

The invention furthermore relates to a process for preparing diphenylazetidinone derivatives of formula I.




Independently of one another, x and y can be from 0 to 10. In compound II,  $-(CH_2)^x-NH_2$  may alternatively also be attached to one of the other two phenyl rings.

The process for preparing the compounds of the formula I comprises reacting an amine of the formula II with an alkylating or acylating agent which, preferably in the omega position, carries a further functionality - if appropriate in protected form. This functionality is (after deprotection) used for attaching (LAG), for example with the formation of ether, amine or amide bonds.

The examples below serve to illustrate the invention in more detail, without limiting the invention to the products and embodiments described in the examples.

## 15 Example I

### N-4-[3-(3-Hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]-benzyl-5-(2,3,4,5,6-pentahydroxyhexylamino)pentanamide (3)



a) N-4-[3-(3-Hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]-benzyl-5-bromopentanamide (2)

416 mg of 1-(4-aminomethylphenyl)-3-(3-hydroxy-3-phenylpropyl)-4-(4-methoxy-

5 phenyl)azetidin-2-one (1) are dissolved in 10 ml of dried dichloromethane, and 0.2 ml of triethylamine is added. With ice-cooling, 200 mg of 5-bromo-  
dissolved in 2 ml of dichloromethane, are added, and the mixture stirred at room  
temperature for 5 hours. 5 ml of water are added, the mixture is acidified using 0.5 N  
HCl (pH ~ 3), the phases are separated, the aqueous phase is washed with a little  
10 dichloromethane, the combined organic solutions are dried with sodium sulfate and  
the residue is, after removal of the solvent, purified by silica gel column filtration.  
This gives 2 as an oil of molecular weight 579.54 ( $C_{31}H_{35}BrN_2O_4$ ) MS (FAB): 581/579  
( $M+H^+$ ).


15 b) N-4-[3-(3-Hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzyl-  
5-(2,3,4,5,6-pentahydroxyhexylamino)pentanamide (3)

300 mg of 2 are dissolved in 10 ml of dimethylformamide, and 191 mg of 6-  
aminohexane-1,2,3,4,5-pentaol are added. The mixture is stirred at 80°C until the  
20 reaction (monitored by thin-layer chromatography) has substantially ended (after  
about 2 hours). The solvent is then removed under reduced pressure and the  
residue is chromatographed on silica gel (mobile phase:  $CH_2Cl_2$  /methanol/conc.  
ammonia = 30:10:2). This gives 3 of molecular weight 679.82 ( $C_{37}H_{49}N_3O_9$ ); MS  
(FAB): 680 ( $M+H^+$ ).

25

## Example II

N-4-1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-1-oxoazetidin-2-  
yl]benzyl-2,3,4,5,6-pentahydroxyhexanamide (4)



a) 4-[5-(4-Fluorophenyl)-1-(4-fluorophenylamino)-5-hydroxy-2-(2-oxo-4-phenyl-oxazolidin-3-carbonyl)pentyl]benzonitrile (5)

5

Under argon, 2.5 g of 3-[5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-oxazolidin-2-one are dissolved in 30 ml of dichloromethane, 3.9 g of 4-[(4-fluorophenyl)imino]methyl]benzonitrile are added and the mixture is cooled to -10°C.

6.4 ml of diisopropylethylamine are added to this mixture and then, over a period of

10 3 min, 4.05 ml of trimethylsilyl chloride such that the temperature does not exceed -5°C. At this temperature, the mixture is stirred for another hour, and it is then cooled to -25°C. 0.8 ml of titanium tetrachloride is then added slowly. The dark mixture is stirred at -25 to -30°C overnight and then decomposed using 35 ml of 7% strength tartaric acid solution, and stirring is continued at room temperature for 1 hour. 15 ml of a 20% strength sodium bicarbonate solution are then added, and the mixture is stirred for another hour. Following phase separation, the org. phase is washed with 30 ml of water, dried over magnesium sulfate and concentrated to about 10 ml. After addition of 2 ml of bistrimethylsilylacetamide, the mixture is heated at reflux for 30 min and then concentrated under reduced pressure. The residue is crystallized

with ethyl acetate/heptane. The product is filtered off with suction and dried under reduced pressure. This gives 5 of molecular weight 653.81 ( $C_{37}H_{37}F_2N_3O_4Si$ ); MS (ESI+): 654.3 ( $M+H^+$ ), 582.2 ( $M+H^+ - Si(CH_3)_3$ ).

5 b) {1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzonitrile (6)

2 g of 5 are dissolved in 20 ml of methyl tert-butyl ether and, with 100 mg of tetrabutylammonium fluoride trihydrate and 1.3 ml of bistrimethylsilylacetamide, 10 heated at 40°C for about 1 h. The reaction is monitored by thin-layer chromatography. After the reaction has ended, initially 0.2 ml of glacial acetic acid is added, and the mixture is stirred for 30 min and concentrated. The residue is treated with 20 ml of a mixture of isopropanol/2N sulfuric acid = 10:1 and stirred for 1 hour. Following the addition of a spatula tip of solid sodium bicarbonate, the mixture is 15 once more concentrated under reduced pressure, the residue is taken up in ethyl acetate, the org. phase is washed with water and dried and the residue is, after removal of the solvent, purified by column chromatography ( $SiO_2$ ,  $CH_2Cl_2$ /methanol = 100:1). This gives 6 of molecular weight 418.45 ( $C_{25}H_{20}F_2N_2O_2$ ); MS (DCI+): 419 ( $M+H^+$ ).

20

c) 4-(4-Aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (7)

200 mg of 6 are dissolved in 20 ml of ethanol and, with 0.5 ml of conc. ammonia, hydrogenated over Raney nickel at a hydrogen pressure of 75 bar and at 25°C for 25 30 hours. The catalyst is filtered off with suction, the filtrate is concentrated under reduced pressure and the residue is purified by column filtration ( $SiO_2$ ,  $CH_2Cl_2$ /methanol/conc.  $NH_3$  = 100:10:1). This gives 7 of molecular weight 422.5 ( $C_{25}H_{22}F_2N_2O_2$ ); MS (DCI+): 423 ( $M+H^+$ ), 405 ( $M+H^+ - H_2O$ ).


d) N-4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzyl-2,3,4,5,6-pentahydroxyhexanamide (4)

50 mg of 7 and 25 mg of 3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one are dissolved in 5 ml of methanol and, together with 10 mg of Na<sub>2</sub>CO<sub>3</sub>, stirred overnight.

5 The mixture is filtered off with suction, the filtrate is concentrated under reduced pressure and the residue is purified by column filtration (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/methanol = 10:1). This gives 4 having a melting point above 180°C and the molecular weight 600.6 (C<sub>31</sub>H<sub>34</sub>F<sub>2</sub>N<sub>2</sub>O<sub>8</sub>); MS (ESI+): 601 (M+H<sup>+</sup>), 583 (M+H<sup>+</sup> - H<sub>2</sub>O).

10 **Example III**

N-4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzyl-12-(2,3,4,5,6-pentahydroxyhexanoylamino)dodecanamide (8)




15 a) 12-(2,3,4,5,6-Pentahydroxyhexanoylamino)dodecanoic acid (9)

3.5 g of 12-aminododecanoic acid are dissolved in 500 ml of methanol and, with 2.7 g of finely powdered sodium carbonate and 4.8 g of 3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one, stirred at room temperature for 30 hours. The mixture is filtered off, the filtrate is concentrated and the residue is dissolved in 70 ml of water. With ice-cooling, 1N hydrochloric acid is added gradually until the pH is 1-2 (about 50-55 ml). The free acid precipitates out and is filtered off with suction, washed with a little cold water, and dried under high vacuum at 35°C. This gives 9 of molecular weight 393.48 (C<sub>18</sub>H<sub>35</sub>NO<sub>8</sub>); MS (ESI+): 394 (M+H<sup>+</sup>); (ESI-):392 (M-H)<sup>-</sup>.

20 b) N-4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzyl-12-(2,3,4,5,6-pentahydroxyhexanoylamino)dodecanamide (8)

is prepared similarly to Example II, starting from 1-(4-aminomethylphenyl)-3-(3-hydroxy-3-phenylpropyl)-4-(4-methoxyphenyl)azetidin-2-one. This gives N-4-[3-(3-hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzyl-12-(2,3,4,5,6-pentahydroxyhexanoylamino)dodecanamide of melting point 100°C and

5 molecular weight 792 ( $C_{44}H_{61}N_3O_{10}$ ); MS (ESI+): 792 ( $M+H^+$ ).




3-[5-(tert-Butyldimethylsilyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one (10)

10 30 g of 3-[5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyloxazolidin-2-one are dissolved in 50 ml of DMF. 14.3 g of imidazole and 19 g of tert-butyldimethylsilyl chloride in 25 ml of DMF are added, and the mixture is then stirred at room temperature until the reaction has gone to completion (2-4 h). The reaction solution is concentrated, water is added and the mixture is extracted with ethyl acetate. The 15 organic phase is dried over magnesium sulfate and concentrated, giving 10:  $C_{26}H_{34}FNO_4Si$  (471.65) MS (ESI) 494 ( $M + Na$ )

3-[(4-Fluorophenylimino)methyl]benzonitrile (11)


20 88 ml of para-fluoroaniline are added dropwise to 12 g of meta-cyanobenzaldehyde in 60 ml of isopropanol. After 1 h at 60°C, the product precipitates out. The mixture is allowed to warm to room temperature and filtered off, and the residue is washed with isopropanol. Drying gives 11 of m.p. 101°C.  $C_{14}H_9FN_2$  (224.24).

3-[5-(tert-Butyldimethylsilyloxy)-5-(4-fluorophenyl)-1-(4-fluorophenylamino)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentyl]benzonitrile (12)



5 At 10°C, 24 ml of diisopropylethylamine are added to 14 g of 3-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one (10) and 12.5 g of 3-[(4-fluorophenylimino)methyl]benzonitrile 11 in 200 ml of methylene chloride, and 7.1 ml of trimethylsilyl chloride are added dropwise. After 1 h, 3.4 ml of titanium tetrachloride are added dropwise at -10°C. The mixture is stirred at -10°C for 3 h and then allowed to stand at -30°C for another 12 h. 8 ml of acetic acid and 140 ml of a 7% strength aqueous tartaric acid solution are then added, and stirring is continued at room temperature for another 2 h. 50 ml of 20% strength aqueous sodium hydrogen sulfite solution are added, and the mixture is then stirred for another hour and extracted with methylene chloride. The organic phase is dried over magnesium sulfate, concentrated and purified by silica gel chromatography (ethyl acetate/heptane = 1/3 -> 1/1). This gives 12  
 $C_{40}H_{43}F_2N_3O_4Si$  (695.89) MS (ESI) 696 (M + H)

20 3-[3-[3-(tert-Butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]benzonitrile (13)




Under argon, a mixture of 13 g of 3-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)-1-(4-fluorophenylamino)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentyl]benzonitrile 12, 50 ml of bistrimethylsilylacetamide, 0.5 g of

5 tetrabutylammonium fluoride and 100 ml of tert-butyl methyl ether is stirred at room temperature for 10 h. After the reaction has ended, 5 ml of acetic acid are added slowly with ice-cooling, and the mixture is concentrated. The residue is separated by silica gel chromatography (ethyl acetate/heptane = 1/8). This gives 13:

10  $C_{31}H_{34}F_2N_2O_2Si$  (532.71) MS (ESI) 555 (M + Na)

3-[1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]-benzonitrile (14)




15 10 ml of 1N hydrochloric acid are added to 7.8 g of 3-[3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]benzonitrile (13) in 200 ml of methanol, and the mixture is stirred for 12 h. Aqueous sodium bicarbonate solution is added to the reaction mixture, which is then extracted with methylene chloride. The organic phase is dried over magnesium

sulfate, concentrated and purified by silica gel chromatography (ethyl acetate/heptane = 1/3 -> 1/1). This gives 14:  $C_{25}H_{20}F_2N_2O_2$  (418.45) MS (ESI) 401 ( $M + H - H_2O$ )

## 5 Example IV

4-(3-Aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-azetidin-2-one (15)




10 In an autoclave, at a hydrogen pressure of 75 bar, 2.5 g of 3-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzonitrile 5 are reacted in 100 ml of ethanol and 15 ml of concentrated ammonia with 1.0 g of Raney-Nickel for 20 h. The reaction solution is filtered, concentrated and separated by silica gel chromatography (methylene chloride/methanol = 10/1). This gives 15:  $C_{25}H_{24}F_2N_2O_2$  (422.48) MS (ESI) 405 ( $M + H - H_2O$ )

15

## Example V

N-3-{2-(4-Fluorophenyl)-4-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl }-benzyl-2,3,4,5,6-pentahydroxyhexanamide (16)




25 mg of sodium carbonate are added to a solution of 100 mg of 4-(3-aminomethyl-

phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one 6 and 46 mg of 3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one in 5 ml of methanol, and the mixture is stirred at room temperature until the reaction has gone to completion. The reaction solution is filtered and concentrated. The residue is 5 purified by HPLC (Knauer Eurospher-100-10-C18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20 -> 10/90). This gives 16:  $C_{31}H_{34}F_2N_2O_8$  (600.62) MS (ESI) 601 (M + H)

### Example VI

10

[3-(3-{2-(4-Fluorophenyl)-4-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl }-benzylcarbamoyl)propyl]trimethylammonium 2,2,2-trifluoroacetate (17)



A solution of 100 mg of 4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (15), 64 mg of 3-carboxypropyltrimethylammonium chloride, 93  $\mu$ l of diisopropylcarbodiimide, 65 mg of hydroxybenzotriazole and 60  $\mu$ l of diisopropylethylamine in 2 ml of methylene chloride is stirred at room temperature for 12 h. Water is added, and the mixture is extracted with methylene chloride. The organic phase is dried over magnesium. 15 sulfate, concentrated and separated by HPLC (Knauer Eurospher-100-10-C18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20 -> 10/90). This gives 17:  $C_{32}H_{38}F_2N_3O_3$  (550.67) MS (ESI) 551 (M + H)


20

### Example VII

25

[3-(3-{2-(4-Fluorophenyl)-4-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-

## y]benzylcarbamoyl)-2-hydroxypropyl]trimethylammonium 2,2,2-trifluoroacetate (18)




18 is prepared similarly to 17 starting from 100 mg of 4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one 15, 64 mg of (3-

5 carboxy-2-hydroxypropyl)trimethylammonium chloride, 93  $\mu$ l diisopropylcarbodiimide, and 65 mg of hydroxybenzotriazole in 2 ml of methylene chloride. Without any extraction step, the reaction solution is concentrated and then purified by HPLC (Merck-Hibar-Lichrospher 100-RP-18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20  $\rightarrow$  10/90). This gives 18:

10  $C_{32}H_{38}F_2N_3O_4$  (566.67) MS (ESI) 567 ( $M + H$ )

## Example VIII




## N-[5-(3-{1-(4-Fluorophenyl)-3-[3-(4-Fluorophenyl)-3-hydroxypropyl]azetidin-2-

15 yl]phenylcarbamoyl)pentyl]-2,3,4,5,6-pentahydroxyhexanamide (19)

19 is prepared similarly to 18 starting from 100 mg of 4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one 15, 108 mg of 6-(2,3,4,5,6-pentahydroxyhexanoylamino)hexanoic acid, 93  $\mu$ l of

20 diisopropylcarbodiimide and 65 mg of hydroxybenzotriazole in 2 ml of methylene chloride. This gives 19:

$C_{37}H_{45}F_2N_3O_9$  (713.78) MS (ESI) 714 ( $M + H$ )




{2-[2-(2,3,4,5,6-Pentahydroxyhexanoylamino)ethoxy]ethoxy}acetic acid (20)

5

172 mg of sodium carbonate are added to a solution of 450 mg of [2-(2-aminoethoxy)ethoxy]acetic acid and 318 mg of 3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one in 10 ml of methanol, and the mixture is stirred at room temperature until the reaction has gone to completion. The reaction solution is filtered and concentrated. The residue is taken up in water and acetonitrile (1/1), resulting in the formation of 2 phases. The aqueous phase is concentrated and contains 20:

C<sub>12</sub>H<sub>23</sub>NO<sub>10</sub> (341.32) MS (ESI) 342 (M + H)

15 Example IX




N-(2-{2-[(3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)methoxy}ethoxy)ethyl)-2,3,4,5,6-pentahydroxyhexanamide (21)

20

21 is prepared similarly to 18 starting from 100 mg of 4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (15), 122 mg of {2-[2-(2,3,4,5,6-pentahydroxyhexanoylamino)ethoxy]ethoxy}acetic acid (20), 93 µl of diisopropylcarbodiimide and 65 mg of hydroxybenzotriazole in 2 ml of

dimethylformamide. This gives 21:  $C_{37}H_{45}F_2N_3O_{11}$  (745.78) MS (ESI) 746 (M + H)



**Example X**

5 N-(2-{2-[(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)methoxy]ethoxy}ethyl)-2,3,4,5,6-pentahydroxyhexanamide (22)


22 is prepared similarly to 18 starting from 100 mg of 4-(4-aminomethylphenyl)-1-(4-

fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one, 122 mg of {2-[2-(2,3,4,5,6-pentahydroxyhexanoylamino)ethoxy]ethoxy}acetic acid 20, 93  $\mu$ l of diisopropylcarbodiimide and 65 mg of hydroxybenzotriazole in 2 ml of dimethylformamide and 1 ml of acetonitrile. This gives 22:

$C_{37}H_{45}F_2N_3O_{11}$  (745.78) MS (ESI) 746 (M + H)

15


2,3,4-Triacetoxy-1-{2-[2-(2-aminoethoxy)ethoxy]acetyl}-5-hydroxypentyl acetate (23)



In a hydrogenation apparatus, a suspension of 1.12 g of 2,3,4-triacetoxy-1-{2-[2-(2-azido-ethoxy)ethoxy]acetyl}-5-hydroxypentyl acetate and 1.0 g of Raney-Nickel in

20 100 ml of ethanol is shaken under an atmosphere of hydrogen for 4 h. The reaction solution is filtered and concentrated. The residue contains 23:

$C_{20}H_{33}NO_{12}$  (479.49) MS (ESI) 480 (M + H)



{2-[2-({2-[2-(3,4,5,6-Tetraacetoxy-7-hydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}-methoxy)ethoxy]ethoxy}acetic acid (24)


5

A solution of 500 mg of 2,3,4-triacetoxy-1-{2-[2-(2-aminoethoxy)ethoxy]acetyl}-5-hydroxypentyl acetate 23, 1.15 g of [2-(2-carboxymethoxyethoxy)ethoxy]acetic acid, 400  $\mu$ l of diisopropylcarbodiimide and 288 mg of hydroxybenzotriazole in 20 ml of methylene chloride is stirred at room temperature for 12 h. The reaction solution is concentrated and separated by HPLC (Knauer Eurospher-100-10-C18, water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) = 80/20  $\rightarrow$  10/90). This gives 24:  $C_{28}H_{45}NO_{18}$  (683.67) MS (ESI) 684 ( $M + H$ )

10

25: [2-({2-[2-(3,4,5,6-Tetraacetoxy-7-hydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}-methoxy)ethoxy]acetic acid (25)


15



20

25 is prepared similarly to 24 starting from 500 mg of 2,3,4-triacetoxy-1-{2-[2-(2-aminoethoxy)ethoxy]acetyl}-5-hydroxypentyl acetate 23, 927 mg of (2-carboxymethoxyethoxy)acetic acid, 400  $\mu$ l of diisopropylcarbodiimide and 288 mg of hydroxybenzotriazole in 20 ml of methylene chloride. This gives 25:  $C_{26}H_{41}NO_{17}$  (639.61) MS (ESI) 640 ( $M + H$ )


{2-[2-({2-[2-(3,4,5,6,7-Pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}-methoxy)ethoxy]ethoxy}acetic acid (26)



5 At room temperature, 100  $\mu$ l of a 5.4 M sodium methoxide solution in methanol are added to a solution of 200 mg of {2-[2-({2-[2-(3,4,5,6-tetraacetoxy-7-hydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}methoxy)ethoxy]ethoxy}acetic acid (24) in 5 ml of methanol, and the mixture is stirred for 2 h. 1 g of Amberlite IR 120 is added to the reaction solution and the mixture is stirred for 10 min, filtered and concentrated, giving 26:

$C_{20}H_{37}NO_{14}$  (515.52) MS (ESI) 516 (M + H)

[2-({2-[2-(3,4,5,6,7-Pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}methoxy)ethoxy]acetic acid (27)




27 is prepared similarly to 26 starting from 200 mg of 25. This gives 27:

$C_{26}H_{41}N1O_{17}$  (471.46) MS (ESI) 472 (M + H)

### Example XI

20

N-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzyl)-2-{2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}methoxy)ethoxy]ethoxy}acetamide (28)




28 is prepared similarly to 18 starting from 62 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one, 76 mg of {2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}methoxy)-

5 ethoxy]ethoxy}acetic acid 17, 57  $\mu$ l of diisopropylcarbodiimide and 40 mg of hydroxybenzotriazole in 2 ml of dimethylformamide. This gives 19:

$C_{45}H_{59}F_2N_3O_{14}$  (919.98) MS (ESI) 920 ( $M + H$ )

### Example XII

10 N-(3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzyl)-2-{2-[2-{2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}methoxy}ethoxy}acetamide (29)




15 29 is prepared similarly to 18 starting from 62 mg of 4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one 15, 76 mg of {2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}methoxy)-ethoxy]ethoxy}acetic acid 26, 57  $\mu$ l of diisopropylcarbodiimide and 40 mg of hydroxybenzotriazole in 2 ml of dimethylformamide. This gives 29:

20  $C_{45}H_{59}F_2N_3O_{14}$  ( 919.98) MS (ESI) 920 ( $M + H$ )

**Example XIII**

N-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzyl)-2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}-

5 methoxy)ethoxy]acetamide (30)




30 is prepared similarly to 18 starting from 68 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one, 76 mg of [2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}methoxy)-

10 ethoxy]acetic acid (27), 62  $\mu$ l of diisopropylcarbodiimide and 44 mg of hydroxybenzotriazole in 2 ml of dimethylformamide. This gives 30:  $C_{43}H_{55}F_2N_3O_{14}$  (875.93) MS (ESI) 876 ( $M + H$ )

**Example XIV**

15

N-(3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}-benzyl)-2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}-methoxy)ethoxy]acetamide (31)




20 31 is prepared similarly to 18 starting from 68 mg of 4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (15), 76 mg of [2-

({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl)methoxy)-ethoxy]acetic acid (27), 62  $\mu$ l of diisopropylcarbodiimide and 44 mg of hydroxybenzotriazole in 2 ml of dimethylformamide. This gives 31:  $C_{43}H_{55}F_2N_3O_{14}$  (875.93) MS (ESI) 876 ( $M + H$ )

5


### Example XV

[3-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)propyl]trimethylammonium trifluoroacetate (32)



10

91 mg of (3-carboxypropyl)trimethylammonium chloride are dissolved in 5 ml of dimethylformamide, and the solution is cooled to 0°C. 0.055 ml of N-methylmorpholine, 210 mg of 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one, 77 mg of N-hydroxybenzotriazole and 15 96 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride are added successively, and the reaction solution is warmed to room temperature and stirred for 12 h. The reaction mixture is concentrated under reduced pressure and the residue is taken up in sat. sodium bicarbonate solution, stirred and concentrated under reduced pressure. Repeatedly, this residue is stirred in acetone and the 20 suspension is filtered. The combined filtrates are concentrated and purified chromatographically (RP18; acetonitrile/water 1/2, with 0.1% trifluoroacetic acid). This gives [3-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)propyl]trimethylammonium; trifluoroacetate of molecular weight 550.67 ( $C_{32}H_{38}F_2N_3O_3$ ; cation); MS (ESI): 551.24 ( $M + H^+$ ).

**Example XVI**

5 Dodecyl-[3-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-  
oxoazetidin-2-yl}benzylcarbamoyl)propyl]dimethylammonium trifluoroacetate (33)

The compound of Example XVI is obtained like that of Example XV, with the difference that, instead of (3-carboxypropyl)trimethylammonium chloride, (3-carboxypropyl)dodecyldimethylammonium chloride is used. This gives

10 dodecyl-[3-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)propyl]dimethylammonium trifluoroacetate of molecular weight 703.96 ( $C_{43}H_{59}F_2N_3O_3$ ; cation); MS (ESI): 704.70 ( $M+H^+$ ).

**Example XVII**

15


Dodecyl-[10-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)decyl]dimethylammonium trifluoroacetate (34)

The compound of Example XVII is obtained like that of Example XV, with the

20 difference that, instead of (3-carboxypropyl)trimethylammonium chloride, (10-carboxydecyl)dodecyldimethylammonium chloride is used. This gives dodecyl-[10-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-

oxoazetidin-2-yl}benzylcarbamoyl)decyl]dimethylammonium trifluoroacetate of molecular weight 803.16 ( $C_{50}H_{74}F_2N_3O_3$ ; cation); MS (ESI): 803.77 ( $M^+$ ).

**Example XVIII**



Benzyl-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}butyl)-(2,3,4,5,6-pentahydroxyhexyl)ammonium trifluoroacetate (35)

a) Methyl 5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoate (36)

At room temperature, 1.37 g of 6-benzylaminohexane-1,2,3,4,5-pentanol are suspended in 30 ml of dry dimethylformamide, 1.45 g of potassium carbonate,

15 0.83 g of potassium iodide and 0.86 ml of methyl 5-bromo-*valerate* are added and the mixture is stirred at room temperature overnight. The next day, the reaction mixture is filtered and the filtrate is concentrated under reduced pressure and, for purification, subjected to chromatography (silica gel; ethyl acetate/methanol/water 5/1/0.1). This gives methyl 5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]-  
20 pentanoate of molecular weight 385.46 ( $C_{19}H_{31}NO_7$ ); MS (ESI): 386.33 ( $M+H^+$ ).

b) 5-[Benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoic acid (37)

At room temperature, 0.46 g of methyl 5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)-amino]pentanoate is dissolved in a mixture of 5 ml of ethanol and 5 ml of water, 0.4 g of potassium hydroxide is added and the mixture is stirred at 80°C for 2 h. The cooled reaction mixture is then concentrated under reduced pressure and the

5 residue is taken up in water, neutralized with hydrochloric acid and again concentrated. The crude product is suspended in ethanol, the suspension is filtered and the filtrate is concentrated under reduced pressure. This gives 5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoic acid of molecular weight 371.43 (C<sub>18</sub>H<sub>29</sub>NO<sub>7</sub>); MS (ESI): 372.2 (M+H<sup>+</sup>).

10

c) 3-[5-(tert-Butyldimethylsilyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one (38)

27 g of 3-[5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyloxazolidin-2-one, 13.6 g

15 of tert-butyldimethylsilyl chloride and 10.2 g of imidazole are dissolved in 36 ml of dimethylformamide, and the mixture is stirred at 60°C for 90 min. After the reaction has ended, the mixture is dissolved in ethyl acetate and extracted twice with water. The organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure. This gives 3-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)-pentanoyl]-4-phenyloxazolidin-2-one of molecular weight 471.65 (C<sub>26</sub>H<sub>34</sub>FNO<sub>4</sub>Si); MS (ESI): 340.28 (MH<sup>+</sup> - HOSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>).

20 d) 4-[5-(tert-Butyldimethylsilyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile (39)

25

16.2 g of 3-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one are dissolved in 350 ml of dichloromethane. 19.8 ml of Hünig base and 10.14 g of 4-[(4-methoxyphenylimino)methyl]benzonitrile are added, and the solution is cooled to -10°C. 85.2 ml of trimethylsilyl triflate are added to the cooled solution, which is stirred at -10°C for 30 min. The solution is then cooled to -30°C,

and 44 ml of titanium tetrachloride solution are added. The reaction mixture is stirred at from -30 to -40°C for 2 h. The reaction solution is then allowed to warm to room temperature and washed successively with 200 ml of 2N sulfuric acid, 300 ml of 20% strength sodium hydrogensulfite solution and sat. sodium chloride solution. The

5 organic phase is dried over magnesium sulfate and concentrated under reduced pressure, and the residue is purified on silica gel using n-heptane/ethyl acetate 3/1. This gives 4-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile of molecular weight 707.93 ( $C_{41}H_{46}FN_3O_5Si$ ); MS (ESI): 590.51 ( $MH^+ - C_7H_5N_2$ ).

10

e) 4-[3-[3-(tert-Butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-2-(4-methoxyphenyl)-4-oxo-azetidin-1-yl]benzonitrile (40)

13.2 g of 4-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphenyl)-

15 2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile are dissolved in 380 ml of methyl tert-butyl ether, 18.6 ml of N,O-bis(trimethylsilyl)acetamide and 1.86 ml of a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran are added and the mixture is stirred at room temperature for 2 h. After the reaction has ended, 10 ml of acetic acid are added, the reaction mixture is concentrated under reduced pressure and the residue is purified on silica gel using toluene/ethyl acetate 50/1. This gives 4-[3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzonitrile of molecular weight 544.75 ( $C_{32}H_{37}FN_2O_3Si$ ); MS (ESI): 545.56 ( $M+H^+$ ).

25 f) 4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzonitrile (41)

3.5 g of 4-[3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzonitrile are dissolved in 65 ml of

30 tetrahydrofuran, 0.74 ml of acetic acid and 8.03 ml of a 1 M solution of

tetrabutylammonium fluoride in tetrahydrofuran are added, and the mixture is stirred at room temperature for 2 h. Another 4.82 ml of the tetrabutylammonium fluoride solution are then added, and the mixture is stirred at reflux temperature for another 3 h. The cooled reaction mixture is concentrated under reduced pressure and the

5 residue is purified chromatographically on silica gel using n-heptane/ethyl acetate 2/1. This gives 4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxo-azetidin-1-yl]benzonitrile of molecular weight 430.48 ( $C_{26}H_{23}FN_2O_3$ ); MS (ESI): 431.24 ( $M+H^+$ ).

10 g) 1-(4-Aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxy-phenyl)azetidin-2-one (42)

1.22 g of 4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzonitrile are dissolved in 90 ml of ethanol, 10 ml of conc. ammonia solution and an excess of Raney nickel are added and the mixture is stirred at 60°C and a hydrogen pressure of 10 bar for 8 h. Overnight, the reaction mixture cools to room temperature. The next day, the catalyst is separated off, the filtrate is concentrated under reduced pressure and the residue is purified chromatographically on silica gel using dichloromethane/methanol/ammonia solution 15 10/1/0.1. This gives 1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)azetidin-2-one of molecular weight 434.51 ( $C_{26}H_{27}FN_2O_3$ ); MS (ESI): 418.2 ( $MH^+ - NH_3$ ).


25 h) Benzyl-(4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}butyl)-(2,3,4,5,6-pentahydroxyhexyl)ammonium trifluoroacetate (35)

At room temperature, 100 mg of 5-[Benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]-30 pentanoic acid and 110 mg of 1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)azetidin-2-one are dissolved in 2 ml of dry

dimethylformamide, 42 mg of N-hydroxybenzotriazole and 52 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride are added and the mixture is stirred at room temperature overnight. The next day, the reaction mixture is concentrated under reduced pressure and, for purification, chromatographed on RP18 using


5 acetonitrile/water with 0.1% trifluoroacetic acid. This gives benzyl-(4-{4-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl}benzylcarbamoyl}butyl)-(2,3,4,5,6-pentahydroxyhexyl)ammonium trifluoroacetate of molecular weight 787.92 ( $C_{44}H_{54}FN_3O_9$ ; cation); MS (ESI): 788.70 ( $M+H^+$ ).

10 **Example XIX**



N-4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzyl-5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanamide (43)

15 The compound of Example XIX is prepared starting from 5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoic acid and 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one similarly to the compound of Example XVIII. This gives N-4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzyl-5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanamide of molecular weight 775.89 ( $C_{43}H_{51}F_2N_3O_8$ );  
 20 MS (ESI): 776.4 ( $M+H^+$ ).


**Example XX**

N-{4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzyl}acetamide (44)

5

The compound of Example XX is prepared by reacting acetic acid similarly to Example XVIII with 1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)azetidin-2-one. This gives N-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzyl}acetamide of molecular weight 476.55 ( $C_{28}H_{29}FN_2O_4$ ); MS (ESI): 477.22 ( $M+H^+$ ).

10

**Example XXI**


5-(9H-Fluoren-9-ylmethoxycarbonylamino)-5-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)pentyl]trimethylammonium chloride (45)

The compound of Example XXI is obtained similarly to the procedure of Example XIX by reacting 4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one with [5-carboxy-5-(9H-fluoren-9-ylmethoxycarbonyl-amino)pentyl]trimethylammonium chloride. This gives [5-(9H-fluoren-9-ylmethoxy-5 carbonylamino)-5-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)pentyl]trimethylammonium chloride of molecular weight 815.99 ( $C_{49}H_{53}F_2N_4O_5$ ; cation); MS (ESI): 815.81 ( $M^+$ ).

### Example XXII

10


[5-Amino-5-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)pentyl]trimethylammonium hydrochloride (46)



15 110 mg of the compound of Example XXI are dissolved in 2 ml of dry dimethylformamide, and 0.1 ml of piperidine are added. The reaction mixture is stirred at room temperature for 2 h and, after the reaction has ended, concentrated under reduced pressure. The residue is stirred in water, filtered off with suction and washed with water, and the filtrate is acidified with 2 N hydrochloric acid. The 20 mixture is concentrated under reduced pressure and the residue is dried under high vacuum. The crude product is suspended in dichloromethane, the organic phase is decanted off and the residue is taken up in methanol, concentrated under reduced pressure and dried under high vacuum. This gives [5-amino-5-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)-

pentyl]trimethylammonium chloride hydrochloride of molecular weight 593.74 ( $C_{34}H_{43}F_2N_4O_3$ ; cation); MS (ESI): 593.37 ( $M^+$ ).

3-[2-[(4-Bromophenyl)-(4-fluorophenylamino)methyl]-5-(tert-butyldimethylsilyloxy)-  
 5 5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one (47)




PCT/US2013/043320

4.4 g of 3-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one are dissolved in 40 ml of absolute dichloromethane. 5.2 g of (4-bromobenzylidene)-(4-fluorophenyl)amine and 8.6 ml of ethyldiisopropylamine are added, and the solution is then cooled to -10°C. 2.94 ml of trimethylsilyl chloride are then added dropwise, and during the addition, the temperature of the reaction mixture is maintained below -5°C. The reaction solution is then stirred at -10°C for 10 half an hour and then cooled to -30°C, and 1.2 ml of titanium tetrachloride are added dropwise, the temperature being maintained between -30°C and -15°C. This gives a black reaction solution which is stirred at -20°C for another 3 h and then allowed to warm to 0°C. In the stated order, in intervals of 10 minutes, 10 ml of glacial acetic acid, 100 ml of 7% strength aqueous tartaric acid solution and finally 100 ml of 20% strength aqueous sodium hydrogensulfite solution are added with stirring. The mixture is then extracted twice with dichloromethane and the organic phase is washed once with saturated sodium chloride solution and dried over sodium sulfate. The solvent is removed using a rotary evaporator and the residue is purified by column chromatography (SiO<sub>2</sub>; ethyl acetate/heptane 1: 4). The product is obtained

from diethyl ether/pentane as white crystals.  $C_{39}H_{43}BrF_2N_2O_4Si$  (749) MS (ESI):  $M^+$


4-(4-Bromophenyl)-3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)azetidin-2-one (48)

5



3.34 g of 3-[2-[(4-bromophenyl)-(4-fluorophenylamino)methyl]-5-(tert-butyl-dimethylsilyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one are suspended in 70 ml of tert-butyl methyl ether. 3.8 ml of bis(trimethylsilyl)acetamide and 144 mg of tributylammonium fluoride trihydrate are then added. The reaction mixture is stirred at room temperature overnight, and 0.7 ml of glacial acetic acid are then added. The reaction mixture is concentrated using a rotary evaporator and the residue is purified by column chromatography ( $SiO_2$ ; ethyl acetate/heptane 1: 4).  
15 The product is obtained as a clear oil.  $C_{30}H_{34}BrF_2NO_2Si$  (586) MS (ESI):  $M^+-131$

3-[5-(tert-Butyldimethylsilyloxy)-5-(4-fluorophenyl)-2-[(4-fluorophenylamino)-(4-hydroxyphenyl)methyl]pentanoyl]-4-phenyloxazolidin-2-one (49)




10 g of 3-[5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one are dissolved in 80 ml of absolute dichlormethane. 9.12 g of 4-[(4-fluorophenylimino)methyl]phenol and 19.6 ml of ethyldiisopropylamine are

5 added, and the solution is then cooled to -10°C. 6.7 ml of trimethylsilyl chloride are then added dropwise, the temperature of the reaction mixture being maintained at below -5°C. The reaction solution is stirred at -10°C for half an hour and then cooled to -30°C, and 2.7 ml of titanium tetrachloride are added dropwise, the temperature being maintained between -30°C and -15°C. This gives a black reaction solution

10 which is stirred at -20°C for another 3 h and then allowed to warm to 0°C. In the stated order, in intervals of 10 minutes, 6 ml of glacial acetic acid, 60 ml of 7% strength aqueous tartaric acid solution and finally 100 ml of 20% strength aqueous sodium hydrogensulfite solution are then added with stirring. The mixture is then extracted three times with dichloromethane and the organic phase is washed once


15 with saturated sodium chloride solution and dried over sodium sulfate. The solvent is removed using a rotary evaporator and the residue is purified by column chromatography (SiO<sub>2</sub>; ethyl acetate/heptane 1: 4). The product is obtained from diethyl ether/pentane as white crystals. C<sub>39</sub>H<sub>44</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub>Si (686) MS (ESI): M<sup>+</sup>-241

20 3-[3-(tert-Butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-(4-hydroxyphenyl)azetidin-2-one (50)



2.63 g of 3-{5-(tert-butyldimethylsilyloxy)-5-(4-fluorophenyl)-2-[(4-fluorophenyl)-amino)-(4-hydroxyphenyl)methyl]pentanoyl}-4-phenyloxazolidin-2-one are suspended in 60 ml of tert-butyl methyl ether. 3.22 ml of bis(trimethylsilyl)acetamide and 122 mg of tributylammonium fluoride trihydrate are then added. The reaction mixture is stirred at room temperature for 3 h, and 0.6 ml of glacial acetic acid are then added. The reaction mixture is concentrated using a rotary evaporator and the residue is purified by column chromatography (SiO<sub>2</sub>; ethyl acetate/heptane 1: 4). The product is obtained as clear crystals. C<sub>30</sub>H<sub>35</sub>F<sub>2</sub>NO<sub>3</sub>Si (523) MS (ESI): M<sup>+</sup>-131

[3-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)propyl]trimethylammonium bromide (51)




210 mg of 3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 4 ml of absolute acetonitrile. 170 mg of KF-alumina (1.15 mol/100 g) and 200 mg of (3-bromopropyl)-

trimethylammonium bromide are then added. The reaction mixture is stirred at room temperature for 4 h and then filtered. The mother liquor is concentrated using a rotary evaporator and the residue is purified using a 5 g  $\text{SiO}_2$  cartridge (dichloromethane/methanol 5: 1). The product is obtained as an oil.

5  $\text{C}_{36}\text{H}_{49}\text{BrF}_2\text{N}_2\text{O}_3\text{Si}$  (703) MS (ESI):  $\text{M}^+-80$

### Example XXIII

[3-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)propyl]trimethylammonium bromide (52)




180 mg of (3-{4-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}propyl)trimethylammonium bromide are dissolved in 10 ml of methanol. 1 ml of a 0.1 M aqueous HCl solution is then added,

15 and the reaction solution is stirred at room temperature overnight. The mixture is neutralized with dilute aqueous sodium bicarbonate solution and concentrated using a rotary evaporator. The residue is purified using a 10 g  $\text{SiO}_2$  cartridge (dichloromethane/methanol 5: 1). The product is obtained as a hygroscopic solid.

$\text{C}_{30}\text{H}_{35}\text{BrF}_2\text{N}_2\text{O}_3$  (589) MS (ESI):  $\text{M}^+-80$

20

[5-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-(tert-butyldimethylsilyloxy)propyl]-4-oxoazetidin-2-yl}phenoxy)pentyl]trimethylammonium bromide (53)




370 mg of 3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 3 ml of absolute

5 acetonitrile. 300 mg of KF-alumina (1.15 mol/100 g) and 375 mg of (3-bromopentyl)-trimethylammonium bromide are then added. The reaction mixture is stirred at room temperature overnight and then filtered. The mother liquor is concentrated using a rotary evaporator and the residue is purified using a 5 g  $\text{SiO}_2$  cartridge (dichloromethane/methanol 4: 1). The product is obtained as an oil.

10  $\text{C}_{38}\text{H}_{53}\text{BrF}_2\text{N}_2\text{O}_3\text{Si}$  (731) MS (ESI):  $\text{M}^+ - 80$

#### Example XXIV


15 [5-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)pentyl]trimethylammonium bromide (54)



548 mg of [5-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-(isopropyldimethylsilanyloxy)propyl]-4-oxoazetidin-2-yl}phenoxy)pentyl]trimethylammonium bromide are dissolved in 20 ml of methanol. 1 ml of a 0.1 M aqueous HCl solution is then added, and the reaction solution is stirred at room temperature overnight. The

5 mixture is neutralized with dilute aqueous sodium bicarbonate solution and concentrated using a rotary evaporator. The residue is purified using a 10 g  $\text{SiO}_2$  cartridge (dichloromethane/methanol 5: 1). The product is obtained as a hygroscopic solid.  $\text{C}_{32}\text{H}_{39}\text{BrF}_2\text{N}_2\text{O}_3$  (617) MS (ESI):  $\text{M}^+-80$

10 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(4-iodobutoxy)-phenyl]azetidin-2-one (55)




15 100 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxy-phenyl)azetidin-2-one are dissolved in 10 ml of absolute dimethylformamide. 80 mg of powdered potassium carbonate and 0.2 ml of diiodobutane are then added. The reaction solution is stirred at room temperature overnight. Following concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified using 20 an  $\text{SiO}_2$  cartridge (n-heptane; n-heptane/ethyl acetate 4: 1). The product is obtained as an oil.  $\text{C}_{28}\text{H}_{28}\text{F}_2\text{INO}_3$  (591) MS (ESI):  $\text{M}^+-18$

**Example XXV**


1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{4-[methyl-(2,3,4,5,6-pentahydroxyhexyl)amino]butoxy}phenyl)azetidin-2-one (56)

5



100 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(4-iodobutoxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute dimethylformamide. 132 mg of 6-methylaminohexane-1,2,3,4,5-pentaol are then added, and the reaction solution is stirred at 50°C for 2 h. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified by preparative HPLC. The product (89 mg) is obtained as an oil. C<sub>35</sub>H<sub>44</sub>F<sub>2</sub>N<sub>2</sub>O<sub>8</sub> (658) MS (ESI): M<sup>+</sup>


15 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(5-iodopentyloxy)-phenyl]azetidin-2-one (57)



150 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 10 ml of absolute dimethylformamide. 120 mg of powdered potassium carbonate and 0.33 ml of diiodopentane are then 5 added. The reaction solution is stirred at room temperature overnight. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified using an SiO<sub>2</sub> cartridge (n-heptane; n-heptane/ethyl acetate 4: 1). The product is obtained as an oil. C<sub>29</sub>H<sub>30</sub>F<sub>2</sub>INO<sub>3</sub> (605) MS (ESI): M<sup>+</sup>-18

10 **Example XXVI**


1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{5-[methyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentyloxy}phenyl)azetidin-2-one (58)



15

170 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(5-iodopentyloxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute dimethylformamide. 220 mg of 6-methylaminohexane-1,2,3,4,5-pentaol are then added, and the reaction solution is stirred at 50°C for 2 h. After concentration using 20 a rotary evaporator and oil pump vacuum at 40°C, the residue is purified by preparative HPLC. The product is obtained as an oil. C<sub>36</sub>H<sub>46</sub>F<sub>2</sub>N<sub>2</sub>O<sub>8</sub> (672) MS (ESI): M<sup>+</sup>


1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(6-iodohexyloxy)-phenyl]azetidin-2-one (59)



5 100 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 10 ml of absolute dimethylformamide. 80 mg of powdered potassium carbonate and 0.25 ml of diiodohexane are then added. The reaction solution is stirred at room temperature overnight. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified using an  $\text{SiO}_2$  cartridge (n-heptane; n-heptane/ethyl acetate 4: 1). The product is obtained as an oil.  $\text{C}_{30}\text{H}_{32}\text{F}_2\text{INO}_3$  (619) MS (ESI):  $\text{M}^+ - 18$

**Example XXVII**

15 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-[methyl-(2,3,4,5,6-pentahydroxyhexyl)amino]hexyloxy)phenyl)azetidin-2-one (60)




136 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(6-iodohexyloxy)phenyl]azetidin-2-one are dissolved in 10 ml of absolute

5 dimethylformamide. 172 mg of 6-methylaminohexane-1,2,3,4,5-pentaol are then added, and the reaction solution is stirred at 50°C for 2.5 h. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified by preparative HPLC. The product is obtained as an oil.  $C_{37}H_{48}F_2N_2O_8$  (686) MS (ESI):

$M^+$

10

1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(8-iodooctyloxy)-phenyl]azetidin-2-one (61)




150 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-

15 hydroxyphenyl)azetidin-2-one are dissolved in 10 ml of absolute dimethylformamide. 120 mg of powdered potassium carbonate and 0.44 ml of diiodooctane are then added. The reaction solution is stirred at room temperature overnight. After

concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified using an SiO<sub>2</sub> cartridge (n-heptane; n-heptane/ethylacetate 4: 1). The product is obtained as an oil. C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>INO<sub>3</sub> (647) MS (ESI): M<sup>+</sup>-18

## 5 Example XXVIII


1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{8-[methyl-(2,3,4,5,6-pentahydroxyhexyl)amino]octyloxy}phenyl)azetidin-2-one (62)



10 150 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(8-iodooctyloxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute dimethylformamide. 180 mg of 6-methylaminohexane-1,2,3,4,5-pentaol are then added, and the reaction solution is stirred at 50°C for 2 h. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified by preparative HPLC. The product is obtained as an oil. C<sub>39</sub>H<sub>52</sub>F<sub>2</sub>N<sub>2</sub>O<sub>8</sub> (714) MS (ESI): M<sup>+</sup>

15

1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(10-iododecyloxy)phenyl]azetidin-2-one (63)



150 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 10 ml of absolute dimethylformamide.


5 120 mg of powdered potassium carbonate and 865 mg of diiododecane are then added. The reaction solution is stirred at room temperature overnight. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified using an  $\text{SiO}_2$  cartridge (n-heptane; n-heptane/ethyl acetate 4: 1). The product is obtained as an oil.  $\text{C}_{34}\text{H}_{40}\text{F}_2\text{INO}_3$  (675) MS (ESI):  $\text{M}^+ - 18$

10

#### Example XXIX

1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{10-[methyl-(2,3,4,5,6-pentahydroxyhexyl)amino]decyloxy}phenyl)azetidin-2-one (64)


15



170 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(10-iododecyloxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute dimethylformamide. 200 mg of 6-methylaminohexane-1,2,3,4,5-pentaol are then

5 added, and the reaction solution is stirred at 50°C for 2 h. After concentration using a rotary evaporator and oil pump pressure at 40°C, the residue is purified by preparative HPLC. The product is obtained as an oil.  $C_{41}H_{56}F_2N_2O_8$  (742) MS (ESI):  $M^+$

10 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-{2-[2-(2-  
iodoethoxy)ethoxy]ethoxy}phenyl)azetidin-2-one (65)




15 150 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 10 ml of absolute dimethylformamide. 120 mg of powdered potassium carbonate and 0.4 ml of 1,2-bis(diiodoethoxy)ethane are then added. The reaction solution is stirred at room temperature overnight. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is  
 20 purified using an  $\text{SiO}_2$  cartridge (n-heptane; n-heptane/ethylacetate 4: 1). The product is obtained as an oil.  $\text{C}_{30}\text{H}_{32}\text{F}_2\text{INO}_5$  (651) MS (ESI):  $\text{M}^+$ -18

**Example XXX**

1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-{4-[2-(2-[methyl-(2,3,4,5,6-pentahydroxyhexyl)amino]ethoxy]ethoxy}ethoxy]phenyl}azetidin-2-one


5 (66)



230 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-{4-[2-(2-iodoethoxy)ethoxy]ethoxy}phenyl)azetidin-2-one are dissolved in 5 ml of absolute dimethylformamide. 280 mg of 6-methylaminohexane-1,2,3,4,5-pentaol are then added, and the reaction solution is stirred at 50°C for 2 h. After concentration using a rotary evaporator and oil pump vacuum at 40°C, the residue is purified by preparative HPLC. The product is obtained as an oil.  $C_{37}H_{48}F_2N_2O_{10}$  (718) MS (ESI):  $M^+$

15

N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)hex-5-enamide (67)




20 1.11 g of 5-hexenoic acid are dissolved in 3 ml of absolute methylene dichloride. 1.4 ml of thionyl chloride are then added dropwise. The mixture is stirred at room

temperature for 3 h and then concentrated using a rotary evaporator. 1.09 g of 6-methylaminohexane-1,2,3,4,5-pentaol are suspended in 5 ml of absolute methylene dichloride. 5-hexenoic chloride dissolved in 3 ml of absolute methylene dichloride is added dropwise, and the mixture is then stirred at room temperature for

5 4 h. The resulting precipitate is filtered off from the reaction product, the filtrate is concentrated using a rotary evaporator and the oily crude product is reacted further without any purification.  $C_{13}H_{25}NO_6$  (291) MS (ESI):  $M^+$

10 N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-{4-[3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenyl}hex-5-enamide  
(68)




15 110 mg of 4-(4-bromophenyl)-3-[3-(tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)azetidin-2-one and 136 mg of N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-hex-5-enamide are initially charged in 300  $\mu$ l of triethylamine under argon in a closed tube which had been heated thoroughly beforehand. After addition of 6 mg of palladium acetate and 14 mg of triphenylphosphine, the mixture is stirred at 100°C for 4 h. The reaction mixture is 20 then taken up in dichloromethane, filtered and concentrated using a rotary evaporator. Purification of the residue using an  $SiO_2$  cartridge (dichloromethane/methanol 20: 1 – 5: 1) gives the product.  $C_{43}H_{58}F_2N_2O_8Si$  (796)

### Example XXXI

## N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenyl)hex-5-enamide (69)

5




70 mg of N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-{4-[3-[tert-butyldimethylsilyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenyl}hex-5-enamide are dissolved in 6 ml of methanol. 0.1 N HCl<sub>(aq)</sub> is then added, and the mixture is stirred at room temperature overnight. The mixture is then neutralized with 1 N aqueous sodium hydroxide solution and concentrated using a rotary evaporator. The residue is stirred with dichloromethane and filtered and the mother liquor is concentrated using a rotary evaporator. The product is obtained following purification by preparative HPLC: C<sub>31</sub>H<sub>44</sub>F<sub>2</sub>N<sub>2</sub>O<sub>8</sub> (682) MS (ESI): M<sup>+</sup>-18

15

### Example XXXII

### 2-{{4-[4-(1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy}butyl}methylamino}ethanesulfonic acid (70)

20




64.5 mg of 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(4-iodobutoxy)phenyl]azetidin-2-one are dissolved in 3 ml of methanol. 60.7 mg of 2-methylaminoethanesulfonic acid are then dissolved in 1 ml of water, and 30.4 mg of potassium carbonate are added. The reaction solution is stirred at 50°C for 8 h. After concentration using a rotary evaporator at 40°C, the residue is passed over a reverse-phase cartridge (methanol). The resulting crude product is dissolved in hot methanol. The precipitate formed on cooling is filtered off, and the mother liquor is concentrated using a rotary evaporator. The product is obtained as an oil.

C<sub>31</sub>H<sub>36</sub>F<sub>2</sub>N<sub>2</sub>O<sub>6</sub>S (602) MS (ESI): M<sup>+</sup>-18

### Example XXXIII

1-(4-Fluorophenyl)-3-[1-(4-fluorophenyl)-2-oxo-4-(4-sulfoxyphenyl)azetidin-3-yl]propyl acetate (71)




120 mg (0.27 mmol) of 1-(4-fluorophenyl)-3-[1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-

4-oxoazetidin-3-yl]propyl acetate are dissolved in 3 ml of pyridine, and 200 mg of Me<sub>3</sub>NSO<sub>3</sub> complex (Aldrich) are added. The suspension is stirred at room temperature for 30 hours. The mixture is then diluted with 5 ml of methylene chloride/methanol/conc. ammonia (30/5/1) and purified by flash chromatography using the same solvent mixture. The product is obtained as an amorphous solid.

5 C<sub>26</sub>H<sub>23</sub>F<sub>2</sub>NO<sub>7</sub>S (531.54) MS (ESI): M<sup>+</sup> = 532.2.

#### Example XXXIV

10 Mono-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenyl) sulfate (72)



PCT/US2013/042061


75 mg (0.14 mmol) of 1-(4-fluorophenyl)-3-[1-(4-fluorophenyl)-2-oxo-4-(4-sulfoxyphenyl)azetidin-3-yl]propyl acetate are dissolved in 2 ml of methanol, and 0.3 ml of

15 1 N NaOMe/MeOH is added. After 2 hours at room temperature, the mixture is neutralized with methanolic hydrochloric acid and concentrated. The residue is purified by flash chromatography. The product is obtained as an amorphous solid.

C<sub>24</sub>H<sub>21</sub>F<sub>2</sub>NO<sub>6</sub>S (489.50) MS (ESI): M<sup>+</sup> = 490.2.

20 **Example XXXV**

2,3,4,5-Tetraacetoxy-1-{3-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}pentyl acetate (73)




112 mg (0.24 mmol) of 1-(3-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)azetidin-2-one are dissolved in 5 ml of methylene chloride and 0.5 ml of triethylamine. At 0°C, 0.5 g of 2,3,4-triacetoxy-1-(acetoxychlorocarbonylmethyl)butyl acetate are added, and the mixture is allowed to thaw to room temperature. After 30 minutes, the mixture is diluted with ethyl acetate and then filtered through silica gel. The solvent is distilled off and the residue is purified by flash chromatography. The product is obtained as an amorphous solid:

5 C<sub>42</sub>H<sub>47</sub>FN<sub>2</sub>O<sub>14</sub> (822.84) MS (ESI): M<sup>+</sup> = 823.3.

10

#### Example XXXVI

15 N-3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzyl-2,3,4,5,6-pentahydroxyhexanamide (74)




90 mg (109 µmol) of 2,3,4,5-tetraacetoxy-1-{3-[3-(4-fluorophenyl)-3-hydroxy-

propyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}pentyl acetate are dissolved in 7 ml of methanol and 0.5 ml of 1 N NaOMe/MeOH is added. After 2 hours at room temperature the mixture is neutralized with methanolic hydrochloric acid and concentrated. The residue is purified by flash chromatography. The product 5 is obtained as an amorphous solid.  $C_{32}H_{37}FN_2O_9$  (612.66) MS (ESI):  $M^+ = 613.2$ .

**Example XXXVII**

10 N-Methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-(4-{3-[1-(4-fluorophenyl)-2-(4-methoxy- phenyl)-4-oxoazetidin-3-yl]-1-hydroxypropyl}phenyl)hex-5-enamide (75)



15 200 mg of N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)hex-5-enamide and 72 mg of 3-[3-(4-bromophenyl)-3-hydroxypropyl]-1-(4-fluorophenyl)-4-(4-methoxyphenyl)-azetidin-2-one are prepared analogously to the synthesis of Example XXXI. The product is obtained as an amorphous solid.

Using the method described below, the activity of the compounds of the formula I according to the invention was examined:

20 **Effect on cholesterol absorption +  $^3H$ -taurocholic acid excretion using fecal excrement of mice, rats or hamsters**

NMRI mice, Wistar rats, or Golden Syrian hamsters (in groups of n=4-6) are kept in metabolic cages, where they are fed with a standard diet (Altromin, Lage (Lippe)). 25 The afternoon prior to the administration of the radioactive tracers ( $^{14}C$ -cholesterol),

the feed is removed and the animals are adapted to grates.

Additionally, the animals are labeled s.c. with  $^3\text{H}$ -TCA (taurocholic acid) (for example 1  $\mu\text{Ci}/\text{mouse}$  up to 5  $\mu\text{Ci}/\text{rat}$ ) 24 hours prior to the peroral administration of the test

5 meal ( $^{14}\text{C}$ -cholesterol in Intralipid® 20, Pharmacia-Upjohn).

Cholesterol absorption test: 0.25 ml/mouse Intralipid ® 20 (Pharmacia-Upjohn) ((spiked with 0.25  $\mu\text{Ci}$  of  $^{14}\text{C}$ -cholesterol in 0.1 mg of cholesterol) is administered perorally by gavage.

10

Test substances are prepared separately in 0.5% methylcellulose (Sigma)/5% Solutol (BASF, Ludwigshafen) or a suitable vehicle.

The administration volume of the test substance is 0.5 ml/mouse. The test substance is administered immediately prior to the test meal (Intralipid labeled with  $^{14}\text{C}$ -cholesterol) (cholesterol absorption test).

15 The feces are collected over a period of 24 h: fecal elimination of  $^{14}\text{C}$ -cholesterol and  $^3\text{H}$ -taurocholic acid (TCA) is determined after 24 hours.

20 The livers are removed and homogenized, and aliquots are incinerated in an oximate (Model 307, Packard) to determine the amount of  $^{14}\text{C}$ -cholesterol which had been taken up/absorbed.

***Evaluation:*****Feces samples:**

The total weight is determined, the sample is made up with water to a defined volume and then homogenized, and an aliquot is evaporated to dryness and

5 incinerated in an oximate (Model 307 from Packard for the incineration of radioactively labeled samples): the amount of radioactive  $^3\text{H}-\text{H}_2\text{O}$  and  $^{14}\text{C}-\text{CO}_2$  is extrapolated to the amount of  $^3\text{H}$ -taurocholic acid and  $^{14}\text{C}$ -cholesterol, respectively, that is excreted (dual isotope technique). The  $\text{ED}_{200}$  values as dose from a dose-effect curve are interpolated as those doses at which the excretion of TCA or

10 cholesterol is doubled, based on a control group treated at the same time.

**Liver samples:**

The amount of  $^{14}\text{C}$ -cholesterol taken up by the liver is based on the administered dose. The  $\text{ED}_{50}$  values are interpolated from a dose-effect curve as the dose at 15 which the uptake of  $^{14}\text{C}$ -cholesterol by the liver is halved (50%), based on a control group.

The  $\text{ED}_{50}$  values below demonstrate the activity of the compounds of the formula I according to the invention

<u>Example No.</u>	<u><math>\text{ED}_{50}</math> (liver) [mg/mouse]</u>
II	0.1
III	0.003
XIII	0.3
25 XV	0.01
XVIII	1.0
XX	0.03
XXI	1.0
XXIV	0.3
30 XXV	0.3
XXX	0.1

As can be seen from the table, the compounds of the formula I have very good cholesterol-lowering action. The compounds can thus be used to control cholesterol concentration. Such control can be by lowering the cholesterol concentration, or

5 maintaining a desired level of cholesterol concentration.

**Bioabsorption:**

The bioabsorption of the compounds of the formula I can be examined using the

10 Caco cell model (A.R. Hilgers et al., Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa, Pharm. Res. 1990, 7, 902).

Below is a bioabsorption measurement for a reference compound:

	Reference structure	Example
15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265<br		